Explore All 2731 Add-on Acquisition Medical Products Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | February 26, 2021 |
| Target | HealthMode |
| Sector | Medical Products |
| Buyer(s) | MindMed |
| Deal Type | Add-on Acquisition |
FILTER BY
| Category | Company |
|---|---|
| Founded | 2019 |
| Sector | Life Science |
| Employees | 74 |
MindMed is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic-inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. MindMed was founded in 2019 and is based in New York, New York.
| Deal Context for Buyer | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Medical Products | 1 of 1 |
| Type: Add-on Acquisition | 1 of 1 |
| State: California | 1 of 1 |
| Country: United States | 2 of 2 |
| Year: 2021 | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-09-16 |
Savant HWP - 18-MC Drug
Reno, Nevada, United States Savant HWP, Inc. - 18-MC Drug is based on the natural psychedelic substance ibogaine and is focused on addressing the opioid crisis and other forms of addiction. Historically, ibogaine has been successful in treating mostly heroin addicts. 18-MC has been synthesized to be non-hallucinogenic while maintaining ibogaine's anti-addictive properties. |
Buy | - |
